Research
Hormonal
Liraglutide was well-tolerated, with benefits experienced by over 90% of patients.
Liraglutide can be considered a safe option for obesity management in clinical practice.
GoodSupportsmedium confidence
Liraglutide was well-tolerated, with its benefits experienced by >90% of patients.
Why this rating
The study is a longitudinal prospective cohort study.
Source
“Super-Responders” to Liraglutide Monotherapy and the Growing Evidence of Efficacy of GLP-1 Analogues in Obesity Management: A Longitudinal Prospective Cohort Study
Ellina Lytvyak et al. · Obesities · 2025
DOI 10.3390/obesities5030063
cohort · n=21
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →